10 August 2026EMALitfulo: adverse event;post-authorisation measure;restriction of indicationAdverse event;Post-authorisation measure;Restriction of indicationMedicine safety communications
6 August 2026EMADesogestrel / etonogestrel: adverse event;post-authorisation measureAdverse event;Post-authorisation measureMedicine safety communications
16 July 2026EMATavneos: referral - article 20 procedureReferral - Article 20 procedureMedicine safety communications
14 July 2026EMAIxchiq: adverse event;restriction of indicationAdverse event;Restriction of indicationMedicine safety communications
12 May 2026EMAOntozry: adverse event;post-authorisation measureAdverse event;Post-authorisation measureMedicine safety communications
11 May 2026EMATecovirimat SIGA: restriction of indicationRestriction of indicationMedicine safety communications
3 April 2026EMAAvtozma: medication error;quality defectMedication error;Quality defectMedicine safety communications
9 October 2025EMACaspofungin: post-authorisation measurePost-authorisation measureMedicine safety communications
26 September 2025EMALeqembi: post-authorisation measurePost-authorisation measureMedicine safety communications
23 September 2025EMAIxchiq: referral - article 20 procedureReferral - Article 20 procedureMedicine safety communications
12 September 2025EMAFinasteride / dutasteride: post-authorisation measurePost-authorisation measureMedicine safety communications